Date: 2012-03-08
Type of information: Commercialisation agreement
Compound: digene HPV Test
Company: Qiagen (The Netherlands) KingMed Diagnostics (China)
Therapeutic area: Cancer Oncology - Infectious diseases
Type agreement: marketing
commercialisation
Action mechanism:
Disease:
Details: Qiagen has announced that it will expand access to its digene HPV Test across China through a co-marketing agreement with KingMed Diagnostics, China’s largest independent laboratory network. Through the agreement, KingMed Diagnostics will function as a centralized lab, allowing smaller hospitals and those in less-populated areas to offer the digene HPV Test and send samples to KingMed Diagnostics for processing and analysis. The agreement is an additional milestone for QIAGEN’s molecular diagnostics franchise in China and its focus on driving growth in emerging markets. The digene HPV Test was first registered in China in 2000 and is now widely available in many of the country’s top-tier hospitals and private labs.
Financial terms:
Latest news:
